1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.

Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans [2012]

Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans [2012]

  1. Behrang
    Drug and Alcohol Dependence 128 (2013) 206– 213

    Lawrence P. Carter, Chad J. Reissig, Matthew W. Johnson, Margaret A. Klinedinst,
    Roland R. Griffiths, Miriam Z. Mintzerd

    - Background: Although concerns surrounding high-dose dextromethorphan (DXM) abuse have recently increased, few studies have examined the acute cognitive effects of high doses of DXM. The aim of this
    study was to compare the cognitive effects of DXM with those of triazolam and placebo.
    - Methods: Single, acute, oral doses of DXM (100, 200, 300, 400, 500, 600, 700, 800 mg/70 kg), triazolam (0.25, 0.5 mg/70 kg), and placebo were administered p.o. to twelve healthy volunteers with histories of hallucinogen use, under double-blind conditions, using an ascending dose run-up design. Effects on cognitive performance were examined at baseline and after drug administration for up to 6 h.
    - Results: Both triazolam and DXM produced acute impairments in attention, working memory, episodic
    memory, and metacognition. Impairments observed following doses of 100–300 mg/70 kg DXM were
    generally smaller in magnitude than those observed after 0.5 mg/70 kg triazolam. Doses of DXM that
    impaired performance to the same extent as triazolam were in excess of 10–30 times the therapeutic
    dose of DXM.
    - Conclusion: The magnitude of the doses required for these effects and the absence of effects on some
    tasks within the 100–300 mg/70 kg dose range of DXM, speak to the relatively broad therapeutic window of over-the-counter DXM preparations when used appropriately. However, the administration of
    supratherapeutic doses of DXM resulted in acute cognitive impairments on all tasks that were examined.
    These findings are likely relevant to cases of high-dose DXM abuse.

    Received 17 April 2012
    Received in revised form 21 August 2012
    Accepted 23 August 2012
    Available online 16 September 2012



    Corrigendum to “Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans” [Drug Alcohol Depend. 128 (2013) 206–213]